Introduction Peripheral T cell lymphomas (PTCL) are a heterogenous group of
lymphoproliferative disorders which are generally not curable with conventional
chemotherapy and associated with inferior outcomes. Pralatrexate is a novel folate analog,
the first FDA approved drug) for the treatment of relapsed/refractory (R/R) PTCL. Areas
covered This paper provides a comprehensive review of PubMed literature describing the
use of pralatrexate in R/R peripheral T-cell lymphoma. Pharmacokinetics and mechanism of …

Abstract Purpose: On September 24, 2009, the US Food and Drug Administration granted
accelerated approval for Folotyn (pralatrexate injection, Allos Therapeutics, Inc.) as a single
agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma
(PTCL); it is the first drug approved for this indication. Experimental Design: This review was
based on study PDX-008, a phase II, single-arm, nonrandomized, open-label, international,
multicenter trial, designed to evaluate the safety and efficacy of pralatrexate when …